Call our Clinical Research Coordinator at 502-589-1500 to find out if participation in any of our studies for Dry Eye Disease, Cataract, Ocular, Allergies, LASIK laser vision correction, Glaucoma, Presbyopia, or Conjunctivitis may be right for you.
We regularly recruit patients (study subjects) to enroll in trials sponsored by pharmaceutical companies, surgical and medical equipment firms, and others attempting to prove the usefulness of a new pharmaceutical agents, treatments, surgical implants or diagnostic medical devices.
All of these clinical studies are done with the ultimate goal of getting the medication, treatment, implant or device to become approved by the United States Food & Drug Administration (FDA).
At The Eye Care Institute, we take your health, wellness and vision very seriously. That’s why we only participate in Phase II, III and IV trials, along with post-marketing studies. Specifically, after the treatment, device, implant or drug has been proven not to be harmful, we then participate in clinical trials to determine how successfully the item being tested works, and for how long.
If you want to be included in a clinical study, please use this form to be considered for treatment of these conditions:
- Dry Eye Disease
- Ocular (eye) allergies
- LASIK laser vision correction
Participation in clinical trials offers patients access to new medications, diagnostic treatments or surgical implants (all at no cost) which may improve the quality of your vision or improve your comfort. Further, your participation may have a positive impact of the lives of patients in the future. Many studies offer compensation for your travel expense and time.
Here is a listing of many of the significant clinical trials in which we have participated (scroll the list to view all):
|Corneal Epithelial Disorder||A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study of SJP-0035 Ophthalmic Solution Compared with Placebo to Assess Safety and Efficacy of Two Dose Concentrations of SJP-0035 Ophthalmic Solution for Corneal Epithelial Wound Healing in Patients with Moderate to Severe Corneal Epithelial Disorders, sponsored by Senju Pharmaceutical Co., Ltd.||October 2016 to Present|
|Dry Eye||Multicenter, Randomized, Controlled, Single-Masked, Cross-Over Clinical Trial to Evaluate the Reduction in the Exacerbation of Dry Eye Symptoms Upon Exposure to a Controlled Adverse Environment (CAE) with Treatment by the Oculeve Intranasal Tear Neurostimulator, sponsored by ORA.||September 2016 to Present|
|Glaucoma||Prospective, Multicenter, Randomized, Double-Masked Clinical Trial To Evaluate The Safety, Efficacy And Dose-Response Of The Bimatoprost Ocular Insert (2.2mg, 13mg) And Timolol (0.5%) Topical Ophthalmic Solution In Patients With Open-Angle Glaucoma Or Ocular Hypertension. Sponsored By ForSight Vision5.||September 2016 to Present|
|Inflammatory Meibomian Gland||Double-Masked, Randomized, Vehicle-Controlled Study to Evaluate the Effect of KPI-121 0.25% Ophthalmic Suspension on Signs and Symptoms of Inflammatory Meibomian Gland Disease.||July 2016 to Present|
|Cataract Surgery||A Phase 3, Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Efficacy of KPI-121 1.0% Ophthalmic Suspension in Subjects With Postsurgical Inflammation and Pain, sponsored by Kala Pharmaceuticals, Inc.||June 2016 to Present|
|Presbyopia||Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating The Safety, Efficacy, And Pharmacokinetics Of The Fixed Combination Of AGN-199201 And AGN-190584 In Patients With Presbyopia.||May 2016 to Present|
|Dry Eye||A Safety and Efficacy Study of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye Disease, sponsored by Mimetogen Pharmaceuticals USA, Inc.||January 2016 to Present|
|Dry Eye||Prospective, Double-Masked, Randomized, Multi-Center, Active-Controlled, Parallel-Group 12 Month Study Assessing The Safety And Ocular Hypertensive Efficacy of PG324 Ophthalmic Solution Compared To AR-13324 Ophthalmic Solution, 0.02% And Latanoprost Ophthalmic Solution, 0.005% In Subjects With Elevated Intraocular Pressure.||September 2015-Present|
|VisAbility Implant System||A Prospective, Multicenter Clinical Trial Of The VisAbility Implant System For Improvement Of Near Visual Acuity In Presbyopic Patients, sponsored by Refocus Group, Inc.||November 2014 to Present|
|Dry Eye||Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution versus Vehicle Control in Subjects with Moderate to Severe Dry Eye Disease (DED), sponsored by Eleven Biotherapeutics, Inc.||March 2014 to Present|
|Cataract Surgery||The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial (Hydrus 4 study), sponsored by Ivantis, Inc.||February 2014 to Present|
|Cataract Surgery||Multi-Center, Double Masked, Vehicle-Controlled, Randomized, Parallel-Group Study to Assess Loteprednol Etabonate Ophthalmic Gel, 0.38% (BID and TID) versus Vehicle Gel for the treatment of Ocular Inflammation and Pain Following Cataract Surgery, sponsored by Bausch & Lomb||February 2014 to August 2014|
|Dry Eye||A Randomized, Multi-Center, Parallel-Group Safety and Efficacy Study of Lotemax Gel 0.5% and Restasis 0.05% for 12 Weeks in Subjects with Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease; DED), sponsored by Bausch & Lomb, Inc.||May 2013 to June 2014|
|Dry Eye||Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Currently Using Artificial Tears (OPUS-2), sponsored by Shire,||December 2012 to October 2013|
|Dry Eye||A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease, sponsored by Bausch & Lomb, Inc.||December 2012 to December 2011|
|Cataract Surgery||Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery, sponsored by Bausch & Lomb, Inc.||May 2011 to December 2011|
|Dry Eye||Efficacy and Safety Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination TID vs. Brinzolamide 1% TID and Brimonidine 0.2% TID, sponsored by Alcon Research.||March 2011 to March 2012|
|Cataract Surgery||Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery, sponsored by Bausch & Lomb, Inc.||June 2008 to November 2008|
|Dry Eye||Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-007), sponsored by Sirion Therapeutics, Inc.||October 22, 2007 to June 29, 2011|
|Glaucoma||A Study of Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients with Open-Angle Glaucoma, sponsored by Alcon Research.||March 2007 to July 2009|
|Glaucoma||Dorzolamide-Timolol as First Line Therapy to Reduce Intraocular Pressure in Patients With Untreated Open Angle Glaucoma (OAG) or Ocular Hypertension (OH), sponsored by Executive Vice President, Clinical and Quantitative Sciences, Merck & Co., Inc.||May 2006 to August 2007|
|Cataract Surgery||A Study of the Glaukos Trabecular Micro-Bypass Stent in Combination With Cataract Surgery in Open Angle Glaucoma Subjects, sponsored by Glaukos Corporation.||June 2005 to March 2010|
|Presbyopia||A Prospective, Multicenter Clinical Trial of the PresVIEW Scleral Implant (PSI) For the Improvement of near Visual Acuity in Presbyopic Patients, sponsored by Refocus Group, Inc.||December 2003 to March 2015|
|Cataract Surgery||Efficacy and Safety of Topical Bromfenac Ophthalmic Solution, 0.09% vs. Placebo for Treatment of Ocular Inflammation Following Cataract Surgery, sponsored by Bausch & Lomb, Inc.||May 2003 to January 2004|
|Corneal Erosion||Topical Dehydrex in Treating Recurrent Corneal Erosion, sponsored by FDA Office of Orphan Products Development.||September 2001 to August 2004|
|Aqueous Dynamics||Effects of AGN 192024 on Aqueous Dynamics, sponsored by Allergan, Inc.||January 2001|
|Glaucoma||A 6-Month, Randomized, Double-Masked Comparison Of Fixed Combination Of Latanoprost And Timolol With The Individual Components, Continuing Into A 6-Month Open Label Safety Study Of Fixed Combination In Patients With Glaucoma Or Ocular Hypertension, sponsored by Pfizer, Inc.||August 1997 to June 1999|
|Herpetic Eye||Herpetic Eye Disease Study (HEDS) II, sponsored by the National Eye Institute (NEI).||October 1992|
|Check back for upcoming trials|
|Ophthalmic Exams||Multiple Contracts for Ophthalmic Exams to Be Coordinated as Needed with Clinical Trials Being Conducted at Norton Healthcare. Sponsored by Norton Cancer Institute.||2014-Present|
Study sponsors, pharmaceutical companies, biotechnology firms and CRO’s: If you wish to consider using our site, please contact us at email@example.com.
The Eye Care Institute is a member of the Society for Clinical Research Sites.